CCNY

Cyclin-Y (Cyc-Y) (Cyclin box protein 1) (Cycl

5,996 patent compounds predicted against CCNY, 4,356 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3936062	0.52	18/20
SCHEMBL4996737	0.56	17/20
SCHEMBL8262703	0.52	17/20
SCHEMBL8262563	0.51	17/20
SCHEMBL8261494	0.53	16/20
SCHEMBL8261343	0.52	15/20
SCHEMBL13993691	0.49	15/20
SCHEMBL8263051	0.52	14/20
SCHEMBL13993665	0.50	14/20
At-7519 (SCHEMBL1069453)	0.59	13/20
SCHEMBL2031219	0.51	13/20
SCHEMBL1286714	0.48	13/20
SCHEMBL8263078	0.48	13/20
At-7519 (SCHEMBL1072294)	0.58	12/20
SCHEMBL2425448	0.55	12/20
SCHEMBL8263999	0.52	12/20
SCHEMBL13993707	0.49	12/20
SCHEMBL13993661	0.52	11/20
SCHEMBL13993706	0.48	11/20
At-7519 (SCHEMBL955568)	0.64	10/20

Germline variants in CCNY on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CCNY gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CCNY by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer	PHASE3	RECRUITING
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients	PHASE3	UNKNOWN
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas	PHASE2	RECRUITING
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer	PHASE2	WITHDRAWN
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors	PHASE2	WITHDRAWN
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6	PHASE2	RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors	PHASE1/PHASE2	COMPLETED
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)	PHASE2	COMPLETED
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors	PHASE2	RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
Abemaciclib + Pembrolizumab In Glioblastoma	PHASE2	WITHDRAWN
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms	PHASE1	COMPLETED
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors	PHASE1	RECRUITING
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Erlotinib in Treating Patients With Barrett Esophagus	PHASE1	UNKNOWN
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy	nan	UNKNOWN
BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast	nan	AVAILABLE
A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study	nan	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma	nan	COMPLETED
The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence	nan	UNKNOWN
Protein Expression in Tumor Tissue Samples From Patients With Cancer of the Oropharynx	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CCNY binder may also engage these)

Protein	Name	Similarity
P34624	—	1.000	P34624 →
Q6NRF4	—	1.000	Q6NRF4 →
Q08CI4	—	1.000	Q08CI4 →
Q5U5D0	—	0.998	Q5U5D0 →
Q4R871	—	0.996	Q4R871 →
Q5T2Q4	—	0.992	Q5T2Q4 →
Q22695	—	0.989	Q22695 →
I2HAA0	—	0.989	I2HAA0 →
P30645	—	0.988	P30645 →
D3YUJ3	—	0.988	D3YUJ3 →
A2A3K4	—	0.987	A2A3K4 →
G5EFD2	—	0.987	G5EFD2 →
A0A8V8TMC4	—	0.987	A0A8V8TMC4 →
O01501	—	0.986	O01501 →
O14328	—	0.985	O14328 →
Q12477	—	0.985	Q12477 →
Q95TJ9	—	0.985	Q95TJ9 →
Q9VM91	—	0.985	Q9VM91 →
Q5ICL9	—	0.985	Q5ICL9 →
Q9XYB7	—	0.984	Q9XYB7 →
O17611	—	0.984	O17611 →
P24867	—	0.984	P24867 →
A6ZZF6	—	0.984	A6ZZF6 →
Q9M0E5	—	0.984	Q9M0E5 →
P34638	—	0.984	P34638 →
Q6ING4	—	0.984	Q6ING4 →
A8KBE0	—	0.984	A8KBE0 →
O01326	—	0.984	O01326 →
A6H8I2	—	0.984	A6H8I2 →
Q8C0T5	—	0.983	Q8C0T5 →